213 66 66 3 3 C. A. Tamminga M. H. Schaffer Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke National Institutes of Health 20205 Bethesda MD USA Manteno Mental Health Center Manteno Illinois USA Department of Psychiatry University of Chicago 60637 Chicago Ill. USA Abstract Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.
End of preview. The entire article is 4 pages. Rent for Free